Skip to content
Pharmacology & Mechanisms

GIP

Glucose-dependent insulinotropic polypeptide, an incretin hormone that enhances insulin secretion and may regulate fat metabolism. Co-targeted alongside GLP-1 by tirzepatide and retatrutide for enhanced weight loss.

Frequently Asked Questions

What is GIP?
Glucose-dependent insulinotropic polypeptide, an incretin hormone that enhances insulin secretion and may regulate fat metabolism. Co-targeted alongside GLP-1 by tirzepatide and retatrutide for enhanced weight loss.
Why is GIP important in peptide research?
GIP is a key pharmacological concept that determines how peptides interact with the body. Understanding this term helps practitioners optimize dosing protocols, predict therapeutic outcomes, and minimize side effects.

Related Terms

GLP-1

Glucagon-like peptide-1, an incretin hormone that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. The therapeutic target of blockbuster drugs semaglutide, tirzepatide, and liraglutide.

Receptor agonist

A molecule that binds to and activates a receptor, triggering a biological response. Semaglutide is a GLP-1 receptor agonist; ipamorelin is a ghrelin receptor agonist.

Related Peptide Profiles

Tirzepatide

A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and weight loss (Zepbound). Achieves 20–25% body weight reduction in clinical trials.

Retatrutide

An investigational triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed 24.2% weight loss at 48 weeks.

← Back to full glossary